Pharmaceutical companies

situation by revealing the problems in pharmaceutical industry, I think the existence of this system still have its eligible reasons

witnessed a dramatic increase in bioterrorism, including Sarin gas attacks in Tokyo, the anthrax attacks post-September 11th (Bodas, et al., 2012). To prepare for a potential bioterrorism attack, or large-scale national emergency, large supplies of pharmaceuticals and medical supplies are stockpiled (Lyon, Taylor, Porter, Prasanna, & Hussain, 2006). This stockpiling of medical supplies is a crucial aspect of the Medical Readiness Strategic Plan, established under the Department of Defense Health Affairs

The pharmaceutical advancement into the medical mainframe having the space to directly sell or prescribe drugs to consumer has raised the bar of concern. A number of factor have caused, especially in regards to the advertisements of the products, the marketing bits, the profit orientation and such like aspects that have made the pharmaceutical agencies to be on the spot of their role in over medication among the consumers of the drugs they promote. The target group that the advertisements of these

Company Overview "CMAX Technologies Inc. is a drug delivery company with expertise in solid oral dosages. The Company was established in 2008 with an objective to provide prompt and reliable services to the Pharmaceutical sector worldwide and to improve the product quality through technological innovations. CMAX Technologies Inc. currently provides assistance to the pharmaceutical industry in developing immediate release and once-a-day drug delivery systems from lab scale to commercial level”

Imagine going into your doctor’s office for an easily treatable illness, and coming out with a slip for an orange bottle full of pills. Now imagine taking them every single day for the next several years because your body has become reliant on these pills to perform properly. Prescription medications have the capacity to do various things to the body. Many of these drugs have been scientifically proven to have successful results by helping patients cure certain diseases or conditions. However, many

(GSK) following a merger to combat bureaucracy in decision making, approval, and authorization. This reorganization was necessary for the continued success of the company. Often the process for drug discovery and market is a slow and tedious process which can cost a company a lot in resources and financially. The smaller biotech companies are able to move quicker and push new drugs to market faster. The shift, Yamada thinks,

“What I learned from the film was that generic drugs are selling better than the branded medication I assume it is because of the cost, of the branded are too high for consumers in the United States to afford to buy it. In the United States the pharmaceutical company’s go through a strenuous trial before they can get a patent for a medication to sell to the public. They are under strict regulations in the United States by the Federal Food & Drug Administration, they go through clinical trials before

With the recent acquisition of Dr. Feel-Good Pharmaceutical, pending company merger will be known as Humanity Driven Pharmaceuticals (HDP), by Global Pharmaceutical Inc. includes two drugs that were in development by Dr. Feel-Good Pharmaceutical. After reviewing financial holdings and assets of Dr. Feel-Good Pharmaceutical and current Global Pharmaceutical Inc. capital, continuing development of both drugs, by HDP, is not financially feasible. Drug A offers parents the possibility of choosing the

with necessity, led to a large R&D push at Merck. By the start of World War II, Merck Research Labs (MRL) was the leading pharmaceutical research institution in the United States. Developments in vitamins, antibiotics, hormones made by Merck boosted its profitability and strengthened its position as leading drug researcher and manufacturer. Merck was seen as a science led company which made breakthrough drugs and theses drugs would sell themselves on its own merits. They had a research driven model

The company operates four segments namely Pharmaceutical, Animal Health, Consumer Care, and Alliance segments (merck.com, 2012). Starting 2011, in order to drive future growth, Merck started focusing on reducing costs, making strategic investments in new product launches, and improving its research and development pipeline. Merck’s sales worldwide reached $48 billion in 2011, which was a 4% increase from 2010. With two drugs under review with the FDA, the company has 19 other drugs